Kimera Labs is a clinical stage biopharmaceutical company that delivered the first placental MSC exosome to the market in 2015. Kimera received IND approval from the FDA for intravenous administration for post-covid inflammation and is now expanding its pipeline across a number of indications with a focus on longevity, aesthetics, neurological disease and organ dysfiunction.
CEO and Founder Kimera Labs Inc
Miami/LA USA
USA
Duncan Ross, Ph.D.
Founder/CEO
Kimera® Labs, Inc.
When his Oceanographer father was diagnosed with acute myeloid
leukemia, and successful options for his particular case were few and
far between, Dr. Duncan Ross committed himself to search for a cure.
To this end, Dr. Ross enrolled in the Ph.D. program at the University
of Miami in Coral Gables, Florida, ultimately obtaining a dual
education in the departments of biochemistry and immunology. Dr.
Ross subsequently became an expert in stem cell culture, developing
proprietary methods of stem cell manipulation and licensing using
growth factors and nucleic acids, methods which are utilized daily in
the work performed by Kimera Labs, the company founded by Dr.
Ross and currently recognized as the leader in the field of
Mesenchymal stem cell (MSC) exosome production.
Dr. Ross’s research in exosome isolation from perinatal cells and amniotic fluid and the
development of cell-free exosome products, has been and continues to be employed by many
physicians and clinics in a variety of aesthetic and regenerative medicine protocols. Dr. Ross has
been featured in various peer reviewed publications including Blood and Biology of Blood and
Marrow Transplantation, and most recently in Nature in October of 2023. As well, Dr. Ross and Kimera Labs have
received FDA Phase I/IIa Investigational New Drug (IND) clearance for a human study utilizing
MSC exosomes.
Dr. Ross is also the founding board member of the nonprofit research organization, The Kimera
Society, which has developed a number of clinical partners in the US and abroad by serving as An educational conduit for clinics
Offer
Since 2012, we have treated over 500,000 patients using the power mesenchymal stem cells and placenta derived MSC Exosomes to treat indications as varying as burns to stroke, renal dysfunction to aging related frailty. Using the combination of focused ultrasound to the brain and intravenous delivery of young FDA IND approved Exosomes, we plan to extend our lifespan well past 100 years and are competing to document this within the longevity XPRIZE as well as a number of independent clinical trials with the FDA and regulatory agencies outside of the US.
NEED
With so many uses for placental MSC Exosomes, we need teams dedicated to funding and delivering each indication to those in need in markets around the world.
Call-to-Action
I invite the participants of this Earth One Community to experience what I and others in our group are achieving for ourselves…be it in lowering our aging markers, recovering from strokes, creating fertility, curing the everyday wound to improving social awareness allowing one to play 4.5 level tennis at the age of 50.
